To address the issue of heavy dialysis burden due to the rising prevalence of end-stage renal disease around the world, a roundtable discussion on the sustainability of managing dialysis burden around the world was held in Hong Kong during the First International Congress of Chinese Nephrologists in December 2015. The roundtable discussion was attended by experts from Hong Kong, China, Canada, England, Malaysia, Singapore, Taiwan and United States. Potential solutions to cope with the heavy burden on dialysis include the prevention and retardation of the progression of CKD; wider use of home-based dialysis therapy, particularly PD; promotion of kidney transplantation; and the use of renal palliative care service.
SUMMARY AT A GLANCE
The First International Congress of Chinese Nephrologists was held in Hong Kong in 2015. This review summarizes the results of a roundtable discussion among international experts in order to cope with the ever-increasing prevalence of end stage renal disease and the resulting heavy dialysis burden.
ABSTRACT:
To address the issue of heavy dialysis burden due to the rising prevalence of end-stage renal disease around the world, a roundtable discussion on the sustainability of managing dialysis burden around the world was held in Hong Kong during the First International Congress of Chinese Nephrologists in December 2015. The roundtable discussion was attended by experts from Hong Kong, China, Canada, England, Malaysia, Singapore, Taiwan and United States. Potential solutions to cope with the heavy burden on dialysis include the prevention and retardation of the progression of CKD; wider use of home-based dialysis therapy, particularly PD; promotion of kidney transplantation; and the use of renal palliative care service.
The prevalence of end-stage renal disease (ESRD) and the demand for renal replacement therapy (RRT) is increasing worldwide. A roundtable discussion on 'dialysis economics: sustainability of managing dialysis burden around the world' was held on 11 December 2015 in Hong Kong during the First International Congress of Chinese Nephrologists.
The roundtable discussion had nephrology opinion leaders and dialysis experts from Hong Kong, China, Canada, England, Malaysia, Singapore, Taiwan and the United States who presented the current situation of RRT ways in addressing the burden of dialysis in their respective localities.
'The incidence and prevalence of ESRD are increasing worldwide. By 2030, the worldwide use of RRT is projected to more than double to 5439 million people with the most growth occurring in Asia. 1 Many ESRD patients in the lowincome countries do not have access to treatment for ESRD and might have died prematurely. 1 Renal replacement therapy is an expensive treatment modality, and the cost of managing a patient on dialysis is estimated to be 6.8-48 times greater than the national average. 2, 3 The choice of the predominant mode of dialysis in many countries is influenced by cultural issues, economic considerations, reimbursement policy and the existing national healthcare system. 4 The pressing issues facing the healthcare providers worldwide are as follows: (i) Will there be enough funding to keep up with patient growth? (ii) Should public policy influence ESRD therapy choice? and (iii) What are the plans to sustain the cost in managing end-stage renal failure patients?'
HONG KONG
In Hong Kong, the incidence of ESRD has increased from 128 pmp. in 2003 to 159 pmp. in 2013. 5 The prevalence of ESRD patients on RRT under the care of the Hong Kong Hospital Authority has increased 15% in 5 years from 2010 to 2014 (Fig. 1) . The Hong Kong Hospital Authority has adopted three strategic approaches to deal with the rising demand for RRT, which include the following: (i) prevention of chronic kidney disease (CKD) and slowing down the progression of CKD by improvement in DM care and diabetic complication assessment, 6 interdisciplinary approach for CKD prevention and enhancement in drug formulary for CKD patients; (ii) facilitation of ESRD patients to live in the community by provision of home-based RRT, such as automated peritoneal dialysis (PD) and nocturnal home haemodialysis (HD), and promotion of haemodialysis public-private partnership programme; and (iii) expansion of the kidney donor pool for transplantation by enhancing the manpower for deceased donor transplant, promoting living-related donor transplant and exploring the feasibility of paired kidney exchange programme in Hong Kong.
CHINA
Chronic kidney disease is a major public health problem in China with a prevalence of 10.8% among the adult population. 7 Although chronic glomerulonephritis is the most common cause of ESRD in China, the proportion of ESRD cases caused by DM is increasing rapidly. The Chinese National Renal Data System (CNRDS) is initiated by the Chinese Society of Nephrology under the leadership of the Ministry of Health of China in 2010. 8 The main objectives of the CNRDS are to collect demographic, clinical and laboratory data for HD and PD cases and to establish a kidney disease database for research and policy making. According to the CNRDS, there were 4047 HD centres and 1031 PD centres in China in 2014. The number of prevalent HD and PD patients was 339 748 and 55 373, respectively (Fig. 2) . The number of patients requiring dialysis is increasing at a rapid pace over the past 10 years, which has put a heavy burden on the national healthcare cost. There is an uneven distribution of dialysis centres in China with the majority of the dialysis centres being concentrated in Beijing, Shanghai, Guangdong and Jiangsu regions. The major challenges facing China are the growing number of ESRD patients and the relatively low proportion of ESRD patients being put on dialysis due to a lack of financial and clinical resources and inequalities in healthcare access. Ongoing healthcare reform in China should increase the prevalence of dialysis in China in future. To meet the rising demand for dialysis, the Chinese Government is advancing the use of PD for the treatment of ESRD. Peritoneal dialysis has the advantages of being a home-based therapy that is convenient to the patients and, more importantly, is less expensive than centre-based HD. Many new PD centres have been established throughout the country. The number of PD patients in China has increased from less than 5000 in 2002 to more than 55 000 in 2014 (Fig. 2) .
CANADA
The global burden of CKD in Canada is rising as a result of increase in the prevalence of DM, hypertension and ageing population. Canada is practicing a universal healthcare system. Although the incidence rate of CKD in Canada has been stabilized in recent years, the prevalence of CKD is increasing because ESRD patients are now living longer (Fig. 3 ). At present, nearly 80% of ESRD patients in Canada are receiving facility-based HD. The remaining 20% of patients are undergoing home-based PD or less commonly home HD. With an increasing recognition of the clinical and economic benefits of home-based RRT, there is a trend towards moving away from facility-based HD to home-based dialysis in Canada.
ENGLAND
To address the burden of dialysis in England, the National Health Service (NHS) encourages primary care physicians to identify people at risk of CKD through appropriate testing and to make timely referrals to secondary care teams. It is hoped that progression of CKD can be prevented or delayed through the early and effective treatment and that cardioand cerebro-vascular risk factors can be addressed to prevent events, such as heart failure and strokes. Early effective patient engagement is also recognized to be crucial if predialysis care is to be optimized with evidence suggesting that such an approach will increase the uptake of home dialysis therapies and pre-emptive kidney transplantation (costeffective treatments that will mitigate the impact of the predicted growth and cost of ESRF treatments). 9 To achieve these aims, the NHS introduced financial incentives: Quality and Outcome Framework scheme for Primary Care and Commissioning For Quality and Innovation (CQUIN) payments for Secondary Care (Fig. 4) although its effectiveness remains controversial. 
MALAYSIA
The prevalence of CKD is rising in Malaysia, which is driven by the increasing age of the population and incidence of DM and other non-communicable diseases.
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Renal replacement therapy is an expensive treatment that consumes a disproportionate share of the healthcare budget. The level of access to dialysis treatment in Malaysia is increasing over time and is exceeding the country's economic growth rate (Fig. 5) . The funding for dialysis in Malaysia comes from the government, charitable organizations, health insurance and patients themselves. In order to reduce the burden of CKD, the Malaysian Government has published clinical practice guidelines on the management of CKD in adults. Measures taken to reduce the cost of RRT include revitalizing renal transplantation, improving PD penetration, consolidation of dialysis centres, increasing dialysis capacity in the public sector and providing medications by the public sector.
SINGAPORE
The incidence of CKD stage 5 in Singapore has increased from 680 [crude rate 210.5 pmp] in 1999 to 1730 in 2014. 12 The most common cause of ESRD is DM and accounts for 65% of the cases (Fig. 6) 
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A mixed financing system based on the 'S and 3M' framework (subsidies [S] and 3M [Medishield, Medisave and Medifund]) is in place to ensure affordability for both outpatient care and inpatient care for all medical problems. Medishield and Medisave are financed through the patient's Central Provident Fund (CPF) that is Singapore's national social security savings plan for citizens and permanent To reduce the number of ESRD cases coming on stream, attention has been paid to improve the affordability of managing the pre-existing conditions that predispose to ESRD as to retard the progression of CKD. The Chronic Disease Management Programme started October 2006 initially covering four chronic diseases now covers 19 conditions, including hypertension, diabetes mellitus and CKD [nephritis/nephrosis]. Claims can be made for consultation, investigations and medications from an approved list. A cap of $400 per month per account is applied, but accounts from relatives may also be used.
To alleviate the burden of dialysis, living kidney donation is actively promoted through publicity campaigns. The NKF's Kidney Live Donor Support Fund assists living donors with reimbursements for costs and lost income due to kidney donation. The Medical Therapy, Education and Research Act (1972) and Human Organ Transplant Act (1987) allow for organ retrieval for deceased donor transplantation. Costs for immunosuppressive agents can be covered by Medishield and its equivalent.
For outpatient dialysis, costs can be covered by various schemes. If a patient does not have employer-provided benefits, he may use the following: In recent years, advanced care planning and option of palliative care are being highlighted to elderly patients and those with multiple comorbidity who may not benefit from dialysis therapy.
TAIWAN
Taiwan has the highest incidence and prevalence of ESRD in the world. The incidence of ESRD is on the increasing trend. 13 Diabetic nephropathy accounts for nearly 45% of the incident ESRD patients. In 2014, the proportion of ESRD patients receiving HD and PD in Taiwan is 91.8% and 8.2% (HD: 73 336 vs. PD 6558 patients), respectively. The increased burden of dialysis in Taiwan is mainly due to the availability of a comprehensive national health insurance programme, increasing the life expectancy of ESRD patients and the low kidney transplantation rate. The control of cost for the dialysis population has resulted in the overall decrease in the ratio of the healthcare cost per dialysis population to the healthcare cost of the general population from 45 times in 2001 down to 28 times in 2013 (Fig. 7) . During this period, the dialysis population has increased from 0.16% of the general population to 0.3%, while the healthcare cost only increased from 7.2% of the overall health budget to 8.3%. 
UNITED STATES
The prevalence of ESRD in the United States is increasing steadily over the past two decades. 14 Nearly 90% of the dialysis population receives HD. The US Government Medicare pays for chronic dialysis of any age. There are almost 450 000 dialysis patients under the Medicare in the United States with an annual spending of 28.6 billion US dollars. A number of strategies are used to cope with the rising dialysis burden, which include emphasis on the prevention of ESRD, encouragement of home-based dialysis modalities (both PD and HD), implementation of performance-based pay system in Medicare and national or international dialogue on appropriateness in starting or withdrawing chronic dialysis. The composite payment with capitation and bundling system has promoted the use of more home-based therapies (Fig. 8 ).
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CONCLUSIONS
The increasing prevalence of ESRD and the growing demand for dialysis to treat ESRD patients are placing a heavy financial burden on the healthcare systems worldwide. The current funding for providing dialysis treatment will not be sustainable in the long run. During the roundtable discussion, it is apparent that countries are pursuing similar potential solutions to cope with the heavy financial burden of providing dialysis: (i) prevention and retardation of the progression of CKD; (ii) wider use of home-based dialysis therapy, particularly PD; (iii) promotion of kidney transplantation; and (iv) introduction of renal palliative care service. However, effective implementation remains a challenge, and it is likely to remain country specific depending on financial, organizational and cultural differences.
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